China Pharma Holdings Inc. to Execute 1-for-10 Reverse Stock Split on April 15

China Pharma Holdings Inc. to Implement Reverse Stock Split

In a strategic move to enhance its stock performance, China Pharma Holdings Inc. (NYSE American: CPHI) has announced a 1-for-10 reverse stock split that will take effect on April 15, 2025. This decision aims to adjust the company’s share price in the market and improve conditions for future investment opportunities.

What the Reverse Stock Split Means

The reverse stock split will convert each ten shares of China Pharma’s outstanding common stock into a single share. As a result, stockholders will retain the same percentage interest in the company; however, the number of shares they own will diminish significantly. Importantly, any fractions of shares that arise from this consolidation will be rounded up to the nearest whole share, ensuring that all stockholders are treated equitably through this shift.

This adjustment was approved by the Company’s Board of Directors through unanimous consent on October 22, 2024. Subsequently, it was ratified by stockholders during the Annual Meeting held on December 22, 2024.

Impact on Trading and Shareholder Value

Starting on April 15, trading will commence on a split-adjusted basis. This change is crucial as it positions the stock for potential future growth by improving perceptions of its value in the eyes of investors. The company's new CUSIP number following the split will be 16941T 401.

China Pharma, a company primarily focusing on specialty pharmaceuticals, anticipates that this move will align its stock performance and market presence with the extensive portfolio it offers. The company develops treatments for prevalent conditions in China, notably cardiovascular, central nervous system disorders, infectious diseases, and digestive issues, highlighting its impact on public health in the region.

About China Pharma Holdings Inc.

Founded to address urgent medical needs, China Pharma is committed to delivering public health solutions through its diverse product offerings. The company operates under a robust business model that prioritizes cost-effectiveness and is bolstered by a strong distribution network that spans all major cities and provinces in China. Its wholly-owned subsidiary, Hainan Helpson Medical Biotechnology Co., Ltd., is based in Haikou City, Hainan Province, playing a pivotal role in the company's operations and distribution strategies.

Future Outlook

As China Pharma navigates this significant organizational change, it also contends with the various challenges of a dynamic industry landscape, including competition and economic shifts within the country. Ahead of this reverse stock split, the company maintains an optimistic outlook on the success of its product offerings and overall market performance.

For more information about China Pharma Holdings, Inc., stakeholders can visit their official website at chinapharmaholdings.com, where important updates and resources are regularly posted.

Safe Harbor Statement

Forward-looking statements in this release are subject to uncertainties that could lead to actual results differing from expectations. Factors influencing these outcomes may include market demand, research and development success, competitive pressures, and broader economic conditions.

This announcement marks a significant milestone for China Pharma, symbolizing its commitment to adapt and thrive in the ever-evolving pharmaceutical landscape.